---
schema_version: "secwatch.filing_event.v1"
accession: "0001485003-23-000014"
form_type: "8-K"
ticker: "CARM"
cik: "0001485003"
company_name: "Carisma Therapeutics Inc."
filed_at: "2023-01-31T23:59:59+00:00"
generated_at: "2026-06-20T05:19:42.075998+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Carisma appoints prominent oncologist to SAB; merger on track for Q1 2023

## Summary
- Padmanee Sharma, MD, PhD, from MD Anderson, appointed to Carisma's Scientific Advisory Board.
- She brings expertise in immuno-oncology for CAR-M and checkpoint inhibitor combination trials.
- Merger with Sesen Bio expected to close in Q1 2023, subject to stockholder approval and conditions.
- Phase 1 trial of CT-0508 + Keytruda actively recruiting; first patient anticipated by end of Q1 2023.
- Merger agreement amended Dec 29, 2022 to deliver greater value to Sesen Bio stockholders.

## SEC filing metadata
- accession: 0001485003-23-000014
- form_type: 8-K
- ticker: CARM
- cik: 0001485003
- company_name: Carisma Therapeutics Inc.
- filed_at: 2023-01-31T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1485003/000148500323000014/0001485003-23-000014-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1485003/000148500323000014/sesn-20230131.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001485003-23-000014
- JSON: https://secwatch.observer/filing/0001485003-23-000014.json
- Plain text: https://secwatch.observer/filing/0001485003-23-000014.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.